Home » Stocks » GLTO

Galecto, Inc. (GLTO)

Stock Price: $5.39 USD -0.10 (-1.82%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 134.39M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 25.26M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $5.39
Previous Close $5.49
Change ($) -0.10
Change (%) -1.82%
Day's Open 5.51
Day's Range 5.31 - 5.55
Day's Volume 49,006
52-Week Range 5.31 - 17.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its ...

3 days ago - GlobeNewsWire

Galecto (GLTO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

2 weeks ago - Zacks Investment Research

BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it...

1 month ago - GlobeNewsWire

Tuesday, March 30, 2021 @ 2pm Eastern Time Tuesday, March 30, 2021 @ 2pm Eastern Time

1 month ago - GlobeNewsWire

Tuesday, March 30, 2021 @ 2pm Eastern Time. Tuesday, March 30, 2021 @ 2pm Eastern Time.

1 month ago - GlobeNewsWire

Galecto expects to continue dosing patients in the 3 mg arm, whereas the 10 mg arm and combinations with nintedanib or pirfenidone will be discontinued at the recommendation of the DSMB Galecto expects ...

1 month ago - GlobeNewsWire

BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced Hans Schambye, the...

2 months ago - GlobeNewsWire

BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the ...

3 months ago - GlobeNewsWire

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that...

4 months ago - GlobeNewsWire

Successfully completed listing on US Nasdaq and raised over $ 150 million during recent IPO and preceding crossover round

4 months ago - GlobeNewsWire

BOSTON and COPENHAGEN, Denmark, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc., a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced t...

5 months ago - GlobeNewsWire

BOSTON and COPENHAGEN, Denmark, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and can...

5 months ago - GlobeNewsWire

The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to raise $750 mil...

Other stocks mentioned: ALGM, AVIR, BDSX, GATO, LESL, LU, MAX ...
5 months ago - Seeking Alpha

Eleven IPOs and nine SPACs priced this past week, getting out ahead of the US election. Markets tumbled and volatility spiked, as several deals broke issue and three IPOs postponed.

Other stocks mentioned: ACICU, AVIR, DSACU, LESL, LUXAU, MAX, ROOT
6 months ago - Seeking Alpha

BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the biological ...

6 months ago - GlobeNewsWire

Galecto has filed proposed terms for an $85 million U.S. IPO. The firm is development treatments for various fibrosis diseases.

6 months ago - Seeking Alpha

About GLTO

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral ... [Read more...]

Industry
Biotechnology
IPO Date
Oct 29, 2020
Stock Exchange
NASDAQ
Ticker Symbol
GLTO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Galecto stock is "Strong Buy." The 12-month stock price forecast is 15.75, which is an increase of 192.21% from the latest price.

Price Target
$15.75
(192.21% upside)
Analyst Consensus: Strong Buy